摘要
目的观察吉非替尼治疗晚期非小细胞肺癌的近期疗效及不良反应。方法32例经放化疗失败的非小细胞肺癌晚期患者,均发生远处转移。口服吉非替尼250mg/次,每天1次,服药中位时间为4个月。结果32例可评价疗效病例中完全缓解0例,部分缓解8例,疾病稳定10例,疾病进展14例,有效率为25.0%(8/32),疾病控制率为56.3%(18/32),中位生存期4.8个月(1～14个月),1年生存率50.0%(16/32)。主要不良反应是皮疹,共有20例(63.5%)。其他不良反应有腹泻、恶心和肝功能损害,无因不良反应退出者。结论吉非替尼治疗晚期非小细胞肺癌有一定疗效,不良反应轻,患者能耐受。
Objective To evaluate the efficacy and toxicities of Gefitinih in patients with advanced non-small cell lung eancer（NSCLC）. Methods 32 patients with advanced NSCLC were in stage IV. Gefitinib was administered orally at 250 mg, once a day until cancer progressed or serve toxicities occurred. The median time for administered of Gufitinih was four months. Resuits Among the 32 patients, 8 patients response （PR） , 10 no change （NC） , and 14 progression disease （PD）. The total response rate was 25.0% （8/32） and disease control rate was 56.3% （18/32）. The median survival time was 4.8 months, The 1-year survival rate was 50.0% （16/32） . The main toxicity of Gefitinib was skin rash . 20 patients had rash,with 63.5% of the whole patients. Conclusion Gifilinib is effective in treatment of advanced NSCLC. The patients had minimum toxicities.
出处
《实用癌症杂志》
2009年第4期384-385,398,共3页
The Practical Journal of Cancer
关键词
非小细胞肺癌
吉非替尼
靶向治疗
表皮生长因子受体
Non-small cell lung cancer（NSCLC）
C, efitinih
Target therapy
Epidermal growth factor reeeptor
